Mark W Kroll insider trades
Open-market stock purchases and sales by Mark W Kroll, Director at Haemonetics Corp, from SEC Form 4 filings since Mar 17, 2010.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +20%.
Open-market stock purchases and sales by Mark W Kroll, Director at Haemonetics Corp, from SEC Form 4 filings since Mar 17, 2010.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +20%.